Table 1. Cytoplasmic Skp2 staining and clinicopathological characteristics of melanomas.
| Variables | Cytoplasmic Skp2 Staining | |||
| Low staining | High staining | Total | P † | |
| All melanoma (n = 436) | ||||
| Age (years) | ||||
| ≤60 | 126 (56.3%) | 98 (43.7%) | 224 (51.4%) | 0.133 |
| >60 | 104 (49.1%) | 108 (50.9%) | 212 (48.6%) | |
| Sex | ||||
| Male | 135 (52.3%) | 123 (47.7%) | 258 (52.8%) | 0.830 |
| Female | 95 (53.4%) | 83 (46.6%) | 178 (47.2%) | |
| AJCC stage | ||||
| I | 112 (67.1%) | 55 (32.9%) | 167 (38.3%) | <0.001‡ |
| II | 54 (43.9%) | 69 (56.1%) | 123 (28.2%) | 0.958§ |
| III | 25 (42.4%) | 34 (57.6%) | 59 (13.5%) | |
| IV | 39 (44.8%) | 48 (55.2%) | 87 (20.0%) | |
| Primary melanoma (n = 290) | ||||
| Age (years) | ||||
| ≤60 | 84 (60.4%) | 55 (39.6%) | 139 (47.9%) | 0.292 |
| >60 | 82 (54.3%) | 69 (45.7%) | 151 (52.1%) | |
| Sex | ||||
| Male | 89 (56.3%) | 69 (43.7%) | 158 (54.5%) | 0.731 |
| Female | 77 (58.3%) | 55 (41.7%) | 132 (45.5%) | |
| Tumor thickness (mm) | ||||
| ≤2.00 | 118 (67.0%) | 58 (33.0%) | 176 (60.7%) | <0.001 |
| >2.00 | 48 (42.1%) | 66 (57.9%) | 114 (39.3%) | |
| Ulceration | ||||
| Absent | 141 (59.5%) | 96 (40.5%) | 237 (81.7%) | 0.005 |
| Present | 25 (47.2%) | 28 (52.8%) | 53 (18.3%) | |
| Site* | ||||
| Sun-protected | 124 (56.6%) | 95 (43.4%) | 219 (75.5%) | 0.707 |
| Sun-exposed | 42 (59.2%) | 29 (40.8%) | 71 (24.5%) | |
| Metastatic melanoma (n = 146) | ||||
| Age (years) | ||||
| ≤60 | 42 (49.4%) | 43 (50.6%) | 85 (58.2%) | 0.109 |
| >60 | 22 (36.1%) | 39 (63.9%) | 61 (41.8%) | |
| Sex | ||||
| Male | 46 (46.0%) | 54 (54.0%) | 100 (68.5%) | 0.437 |
| Female | 18 (39.1%) | 28 (60.9%) | 46 (31.5%) | |
*Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.
†
χ2 test.
‡
Comparison between all AJCC stages.
§
Comparison between AJCC stage II, III and IV.